UMGCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
ProtocolsBack To Search Instructions
133 protocol(s) meet the specified criteria
Protocol No.TitleStatus
0605GCCA Phase II Study Evaluating Bone Marrow-Sparing, Image-Guided Pelvic Intensity-Modulated Radiotherapy (IMRT) with Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients with High Risk, Non-Metastatic Prostate Cancer. Open
0631RTOGPHASE II/III STUDY OF IMAGE-GUIDED RADIOSURGERY/SBRT FOR LOCALIZED SPINE METASTASISOpen
0848RTOGRTOG 0848, A Phase IIR and A Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaOpen
0858GCCVIRTUAL REALITY AND ACUTE PAIN MANAGEMENT FOR CHILDREN: PILOT TESTING OF VIRTUAL REALITY FOR INVASIVE MEDICAL PROCEDURES IN PEDIATRIC ONCOLOGY PATIENTS Open
0920RTOGA PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCEROpen
0924RTOGAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialOpen
1016GCCThe Role of NKT cells in Breast Cancer Patients and Healthy VolunteersOpen
1112RTOGRandomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma Open
1122GCCObservational Study of hepatic metastasis of colorectal originOpen (affiliates only)
1129GCCAn Open Label Assessment Of Safety And Efficacy Of Ruxolitinib (INCB018424) In Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis And Post Polycythemia Veramyelofibrosis Who Have Platelet Counts Of 50 X109/L To 100 X109/LOpen
1150GCCA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications.Open
1167GCCA PILOT PROSPECTIVE CASE CONTROL STUDY OF AROMATASE INHIBITOR-ASSOCIATED MUSCULOSKELETAL SYMPTOMS (AIMSS) AND AUDIOLOGIC ABNORMALITIES AFTER AROMATASE INHIBITOR USEOpen
1202GCCGCC1202 : Tumor Bed Dose Delivery using a Breast Specific Radiosurgery Device, The GammaPodTM: A Clinical Feasibility StudyOpen
1224GCCPhase II Trial of Low-Dose Whole Brain Radiotherapy with Concurrent Temozolomide and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma MultiformeOpen
1238GCCDemethylating agents in patients with MDS and marow fibrosis Open
1271GCC1271GCC: A Characterization of Myelofibrosis in Black Patients at a Single InstitutionOpen
1304RTOG/NSABP-B-51RTOG1304/NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyOpen
1306RTOGA RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)Open
1308GCCPROTOCOL EC1456-01: A PHASE 1 STUDY OF FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSOpen
1314GCCPhase II Trial of Low Dose Whole Pelvic Radiotherapy with Concurrent Neoadjuvant FOLFOX for Patients with Newly Diagnosed T3N0M0, T2N1M0, and T3N1M0 Rectal AdenocarcinomaOpen
1324GCCNeoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients with Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study Open
1344GCCPILOT STUDY OF COMBINED OPTUNE, BEVACIZUMAB, AND HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR BEVACIZUMAB-NAIIVE, RECURRENT GLIOBLASTOMA Open
1366GCCA PROSPECTIVE STUDY OF NEOADJUVANT NON-STEROIDAL AROMATASE INHIBITORS IN POSTMENOPAUSAL WOMEN WITH OPERABLE HORMONE RECEPTOR-POSITIVE BREAST CANCER TO EVALUATE THE ANTI-PROLIFERATIVE RESPONSE IN OBESE AND OVERWEIGHT PATIENTSOpen
1367GCCAn Umbrella Protocol for Collection of Blood, Bone Marrow, Lymph Node Specimens and Buccal Samples from Patients with Established or Suspected Leukemia, Myeloma, Lymphoma or Related Disorders and Normal Subjects, to be used in Laboratory ResearchOpen
1368GCCCelsion 105-08-201: A PHASE I-II STUDY EVALUATING THE MAXIMUM TOLERATED DOSE, BIOEQUIVALENCE/PHARMACOKINETICS, SAFETY, AND EFFICACY OF HYPERTHERMIA AND THERMODOX (LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN) IN PATIENTS WITH LOCAL-REGIONAL RECURRENT BREAST CANCEROpen
1378GCCA STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA) Open
1380GCC1380 GCC: GP-88 AS SCREENING TEST FOR BREAST CANCEROpen (affiliates only)
1403GCCAn Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal breast tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Breast Malignancy and Normal Subjects, to be used in Laboratory ResearchOpen
1404GCC1404GCC: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line ChemotherapyOpen
1424GCCA Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
1425GCCInhibition of Pim kinases in acute myeloid leukemia Open
1430GCCCelldex CDX 011: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The METRIC Study)Open
1456GCC1456GCC: A Phase II trial of reirradiation combined with open label MK-3475 in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN)Open
1465GCC1465GCC: A Pilot Study and Phase II Single Institution Double Blind Placebo Controlled Randomized Trial Examining the Safety and Efficacy of Glyburide as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain MetastasesOpen
1467GCC1467GCC: RANDOMIZED PHASE II EVALUATION OF CARBOPLATIN/PACLITAXEL WITH AND WITHOUT TRASTUZUMAB (HERCEPTIN®) IN HER2/neu+ PATIENTS WITH ADVANCED/RECURRENT UTERINE SEROUS PAPILLARY CARCINOMAOpen
1468GCC1468GCC: Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomasOpen
1470RTOGA Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)Open
1475GCCA Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
1488GCCCollection of Tissue Samples from Women with Gynecologic Malignancies and Healthy Controls for Laboratory Research Open
1491GCC1491GCC: Feasibility and Outcomes of Allogeneic (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with AML or High-Risk MDSOpen
1495GCC1495GCC: An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Thoracic Malignancies and Normal Subjects, to Be Used in Laboratory ResearchOpen
1504GCCRandomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)Open
1506GCC1506GCC: Peripheral blast clearance versus day 14 bone marrow biopsy for predicting achievement of complete remission in adult patients with acute myeloid leukemiaOpen
15100GCCPragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium TrialOpen
15106GCC15106GCC - TRUST-Anal Cancer StudyOpen
1524GCCA Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer [GO24931]Open
1527GCCA Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy Open
1530GCCA Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesOpen
1533GCC1533GCC: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Open
1534GCC A pilot study to evaluate inflammatory markers in patients receiving pelvic radiation therapy and Pediococcus-based probioticsOpen
1538GCC1538GCC: Hyperbaric oxygen therapy for hematopoietic progenitor cell collection in poor mobilizersOpen
1541GCC1541GCC: Phase III Open-Label, Multicenter, Randomized Study of ASP2215 vs. Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 MutationOpen
1543GCC1543GCC: Molecular profiling of gynecologic cancersOpen
1547GCCULTRASOUND-BASED BLADDER SCANNING FOR REPRODUCIBILITY OF BLADDER-FILLING DURING ABDOMINOPELVIC EXTERNAL BEAM RADIOTHERAPYOpen
1548GCCA Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)Open
1550GCCRandomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After ChemotherapyOpen
1554GCCA Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesOpen
1555GCCA Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC).Open
1556GCCA Phase I/ II Dose Escalation Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC).Open
1562GCCA Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Open
1564GCCPhase I trial of brentuximab vedotin combined with re-induction chemotherapy in patients with relapsed or refractory, CD30-expressing acute myeloid leukemia (AML).Open
1565GCCMulticenter phase 1/2 study of combination therapy with the DNA methyltransferase inhibitor decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AMLOpen
1566GCCA Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung Cancer, and Other B7-H3-Expressing CancersOpen
1567GCC1567GCC: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Open
1569GCCA Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer_PCG LUN005-12Open
1570GCC PCG-BRE007-12: Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Open
1571GCCBRE008-12: Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node IrradiationOpen
1572GCC1572GCC: Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual MyelomaOpen
1575GCC1575GCC: Comparative analysis of outcomes of allogeneic stem cell transplantation (Allo-HSCT) for patients with acute myeloid leukemia (AML) treated with conventional chemotherapy versus DNA methyltransferase inhibitors (DNMTIs)Open
1578GCCPhase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed. NCI 9837, PhI-76Open
1579GCCA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentOpen
1583GCCA Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate_ GU002-10 Open
1589GCC1589GCC: PDL1, B7H3, and PD-1 expression in Cutaneous SCCOpen
1590GCC1590GCC: A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid or Hematological MalignanciesOpen
1593GCC1593GCC: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) [56021927PCR3002]Open
1594GCCAN OPEN-LABEL, SINGLE-ARM, PHASE II STUDY OF PERTUZUMAB WITH HIGH-DOSE TRASTUZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM PROGRESSION POST-RADIOTHERAPY IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER (PATRICIA)Open
1600GCC1600GCC: GS-US-296-0101: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid TumorsOpen
1601GCCAn Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide ProphylaxisOpen
1603GCCAnalysis of cell-free DNA (cfDNA) in men with elevated PSA levelsOpen
1604GCCA randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast CancerOpen
1607GCCA Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)Open
1611GCCPhase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma FusionOpen
1614GCC Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1619GCC Modeling respiration-induced motion and deformation of tumors and thoracic organs for personalized motion management in lung SBRT Open
1629GCC1629GCC: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy Naive stage IV Non-small Cell Lung CancerOpen
1631GCC1631GCC: Protocol 20150253 An observational study of patients with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the USOpen
1632GCC1632GCC: A Phase 1/1b, Multicenter, Open-Label, Dose-Escalation Study of FT 2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 MutationOpen
1635GCC Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereo-tactic Ablative Body Radiotherapy (SAbR) Open
1638GCCA Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaOpen
1639GCC1639GCC: A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer (I4D-MC-JTJH)Open
1645GCCA Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic DiseaseOpen
1647GCC1647GCC: Retrospective chart review of chemoprevention utilization for atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in-situ in an urban population with a high minority subsetOpen
1660GCC1660GCC: Human Aspartyl-(Asparaginyl)-β-Hydroxylase (HAAH) as a biomarker in acute myeloid leukemia (AML).Open
1693GCC-EU1693GCC-EU Compassionate use of ASP2215 in patient PBOpen
30610CALGBPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and EtoposideOpen
341256Implementation of evidence-based cancer early detection in Black churchesOpen (affiliates only)
3508RTOGA Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) Open
375044African American and Colo-rectal Cancer: A Multilevel Model to Assess Factors that may explain CRC Health DisparitiesOpen (affiliates only)
380462Behavioral Intervention to Reduce Breast Cancer Disparity in Under served KoreansOpen (affiliates only)
697531Examining Patient Understanding of Colonoscopy Results: Implications of Health LiteracyOpen
A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III studyOpen
A011202A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPYOpen (affiliates only)
A081105ALCHEMIST: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Open
A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Open
AALL1231AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)Open
AALL1331AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
AAML1331AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid. Open
AHOD1331AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (Bv, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and AdolescentsOpen
ALTE07C1ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with CancerOpen
APEC14B1APEC14B1: THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDYOpen
E1910E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in AdultsOpen
E2112A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast CancerOpen
E4512ALCHEMIST: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
EA5142EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung CancersOpen
EAY-131EAY- 131 Molecular Analysis for Therapy Choice (MATCH) Open
GCC15104Performance Evaluation of N Latex FLC kappa and lambda on BN™ Systems Open
HP-00059927HUDHumanitarian Use Device: Miltenyi Biotec's CliniMACS CD34 Reagent SystemOpen
N1048N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal ExcisionOpen
NRG-BN001RANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED DOSE-ESCALATED PHOTON IMRT OR PROTON BEAM THERAPY VERSUS CONVENTIONAL PHOTON IRRADIATION WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAOpen
NRG-BN002PHASE I STUDY OF IPILIMUMAB, NIVOLUMAB, AND THE COMBINATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Open
NRG-BR001A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple MetastasesOpen
NRG-BR002A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerOpen
NRG-BR003NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Open
NRG-CC001A Randomized Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases Open
NRG-CC003RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER Open
NRG-HN002A RANDOMIZED PHASE II TRIAL FOR PATIENTS WITH p16 POSITIVE, NON-SMOKING ASSOCIATED, LOCOREGIONALLY ADVANCED OROPHARYNGEAL CANCER Open (affiliates only)
NRG-LU001RANDOMIZED PHASE II TRIAL OF CONCURRENT CHEMORADIOTHERAPY +/- METFORMIN HCL IN LOCALLY ADVANCED NSCLC Open
NSABP-B-55NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs. Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyOpen
S0820S0820, A Double Blind Placebo-Controlled Trial of Eflornithine andSulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)Open
SWOG1207SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine TherapyOpen
SWOG1400S1400 PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCEROpen
SWOG1400BS1400 PHASE II/II BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCER; S1400B A PHASE II/III RANDOMIZED STUDY OF GDC-0032 VERSUS CHEMOTHERAPY AS SECOND LINE THERAPY FOR BIOMARKER SELECTED PATIENTS WITH SQUAMOUS CELL LUNG CANCER Open
SWOG1400IS1400I A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)Open